Videos
Round 2: Frontline Therapy for Patients With CNS Disease and Other High-Risk Features
10/28/2026
The discussion turns to a patient with baseline CNS metastases and a TP53 co-mutation. Panelists explore CNS efficacy, differences in trial assessment methods, and how high-risk disease characteristics influence treatment selection.
To see arguments related to frontline therapy for the newly diagnosed patient, see Round 1.
To see arguments related to frontline therapy across age and fitness levels, see Round 3.
Transcript coming soon!
©️ 2026 HMP Global. All Rights Reserved.
This is a non-CME activity. The views and opinions expressed by the presenter(s) do not necessarily reflect the views and opinions of the Oncology Learning Network, HMP Global, or its employees and affiliates.
